TRIAL DETAIL
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 10/01/2007 |
Age of Trial (yrs) 17.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
PI3K inhibitor |
|||
Strategy: |
Block KIT Signal Path |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
GDC4255g |
|||
Sponsor: |
Genentech |
|||
Patient Contact: |
See site contact info below |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This drug was initially developed by Piramed in the United Kingdom. GDC-0941 selectivity has not yet been published, so this information is unknown. We have been told informally that this oral drug inhibits multiple class I PI3K’s. It is currently in trial at Dana Farber in Boston, Mass. under George Demetri, MD. |
|||
Trial Links |
Trial Results |
Drug Information |
| The identification of GDC-0941 |
| Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
450 Brookline Ave |
Boston |
MA |
02215-5450 |
USA |
|
10460 N. 92nd Street, Suite 206 |
Scottsdale |
AZ |
85248 |
USA |
|
4100 John R |
Detroit |
MI |
48201 |
USA |